{"id":"W4308977441","doi":"10.1093/neuonc/noac209.318","title":"CTNI-53. PNOC014: PHASE IB STUDY RESULTS OF DAY101(TOVORAFENIB) FOR CHILDREN WITH LOW-GRADE GLIOMAS (LGGS) AND OTHER RAS/RAF/MEK/ERK PATHWAY-ACTIVATED TUMORS","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Dosing; Body surface area; MAPK/ERK pathway; Toxicity; MEK inhibitor; Adverse effect; Internal medicine; Oncology; Nuclear medicine; Kinase; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008956178,0.0007440151,0.0009703532,0.0002102182,0.0002351511,0.0007314329,0.0006109453,0.0004563696,0.001992178],"category_scores_gemma":[0.0004884832,0.0002267807,0.0005573473,0.0002772625,0.0005006614,0.0003367633,0.0002077957,0.001689828,0.0005780333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001194639,"about_ca_system_score_gemma":0.002011921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003188748,"about_ca_topic_score_gemma":0.01282052,"domain_scores_codex":[0.9997097,0.0001332434,0.00001635434,0.00003672479,0.00003828327,0.00006573384],"domain_scores_gemma":[0.9996132,0.00005254475,0.00005936535,0.00002712542,0.00002507175,0.0002227735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2409606,0.0342326,0.02321599,0.002187481,0.001416072,0.001492741,0.0005948239,0.01260424,0.3725018,0.001298548,0.01303852,0.2964566],"study_design_scores_gemma":[0.177667,0.606328,0.07765235,0.0002083029,0.001205402,0.003711852,0.0001791091,0.00542817,0.0993968,0.0004520762,0.02764949,0.0001214178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908449,0.002148528,0.0006865479,0.0003628696,0.00006179886,0.0009815493,0.001720162,0.000128401,0.003065331],"genre_scores_gemma":[0.9877254,0.001687674,0.002250837,0.000281475,0.00003694991,0.0007973325,0.004279011,0.00005915755,0.002882038],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003188748,"threshold_uncertainty_score":0.008667767,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02433929911267178,"score_gpt":0.310047491248283,"score_spread":0.2857081921356112,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}